Constantine S. Tam, MD, MBBS

Articles

BTK Inhibitors in CLL: Second Generation Drugs and Beyond

May 30th 2024

Dr. Constantine Tam provides an overview of the current and emerging treatment landscape for chronic lymphocytic leukemia (CLL), with a focus on Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib and the next generation of BTK inhibitors under development.

Broad Superiority of Zanubrutinib Over Bendamustine + Rituximab Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without del(17p)

December 21st 2023

Constantine S. Tam, MD, MBBS, presents the biomarker subgroup analysis from the phase 3 SEQUOIA study investigating zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p).

Rate of Atrial Fibrillation in Patients With B-Cell Malignancies Who Undergo Treatment With Zanubrutinib

December 8th 2022

Sponsored by BeiGene. Content developed independently by OncLive. Dr Tam reviews the risk of atrial fibrillation along with other cardiovascular events in patients who either receive ibrutinib or zanubrutinib for b-cell malignancies.

Dr. Tam on FDA Approved BTK Inhibitors in Hematologic Malignancies

February 12th 2020

Constantine S. Tam, MD, MBBS, discusses the 3 FDA approved BTK inhibitors in hematologic malignancies: ibrutinib, acalabrutinib, and zanubrutinib.

Dr. Tam on Zanubrutinib Approval in MCL

February 12th 2020

Constantine S. Tam, MD, MBBS, discusses the FDA approval of zanubrutinib in mantle cell lymphoma.

Dr. Tam on Varying BTK Inhibitors in Mantle Cell Lymphoma

January 8th 2020

Constantine S. Tam, MD, MBBS, discusses a comparison of BTK inhibitors in mantle cell lymphoma.

Dr. Tam on Results of the CAPTIVATE Trial in CLL

December 8th 2019

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).